Back

Sotatercept improves echocardiographic risk stratification in pulmonary arterial hypertension: real-world data from the french early access program

29 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy and the spectrum of left ventricular hypertrophy Morphology, Dimensions, Volumes and Mass ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Manel EL BLIDI

Hopital Bicetre, Le Kremlin-Bicetre (France)

6 More presentations in this session

Presentation thumbnail
Atrial reverse remodelling and restored atrioventricular coupling define diastolic recovery during mavacamten therapy in obstructive hypertrophic cardiomyopathy
Doctor P. Craciun (Bucharest, RO) Miss S. Gonzalez De Alaiza (ES)
Abstract Slides Video
Presentation thumbnail
Diastolic reserve restoration drives functional improvement under mavacamten in obstructive hypertrophic cardiomyopathy: a real-world CPET–echocardiography study
Mr J. Broustaille (Rennes, FR)
Abstract Slides Video
Presentation thumbnail
Predicting five-year mortality in patients with left ventricular hypertrophy based on dynamic radiomics from transthoracic echocardiography
Mr P. Su (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Systematic misclassification of left ventricular mass by echocardiography is driven by ventricular geometry: a CT-based reference analysis
Doctor S. Fathieh (London, GB)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic markers of left atrial remodeling as predictors of diastolic dysfunction
Associate Professor L. Bikdelu (Mashhad, IR)

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy and the spectrum of left ventricular hypertrophy

The Event

Event poster

ESC Congress 2026

29 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Enhancing risk stratification in pulmonary hypertension: integrating echocardiographic parameters with the REVEAL Lite 2.0 score
30 August 2025
thumbnail
Congress Presentation
Sotatercept as an alternative therapeutic strategy in high-risk pulmonary hypertension associated with systemic sclerosis and interstitial lung disease when prostacyclin therapy is not feasible
29 August 2026
thumbnail
Congress Presentation
Representativeness of randomized clinical trial criteria among the real-world patients with pulmonary arterial hypertension: an analysis from the FOCUS-PAH registry
30 August 2025
thumbnail
Congress Presentation
Effects of sacubitril/valsartan on left and right ventricular function during and after breast cancer therapy: a randomised placebo-controlled trial
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources